AIA Group Ltd lifted its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 24.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 930,933 shares of the medical research company's stock after buying an additional 181,409 shares during the quarter. Edwards Lifesciences makes up about 1.7% of AIA Group Ltd's portfolio, making the stock its 9th biggest position. AIA Group Ltd owned 0.16% of Edwards Lifesciences worth $68,917,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in shares of Edwards Lifesciences by 10.4% in the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock valued at $5,117,845,000 after purchasing an additional 6,537,494 shares during the period. Wellington Management Group LLP raised its position in Edwards Lifesciences by 5.3% during the 4th quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company's stock valued at $2,458,601,000 after purchasing an additional 1,678,154 shares in the last quarter. State Street Corp lifted its holdings in shares of Edwards Lifesciences by 1.0% in the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company's stock worth $1,733,270,000 after buying an additional 256,538 shares during the period. Geode Capital Management LLC grew its position in shares of Edwards Lifesciences by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company's stock worth $889,050,000 after buying an additional 284,918 shares in the last quarter. Finally, Fisher Asset Management LLC increased its stake in shares of Edwards Lifesciences by 7.7% during the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company's stock valued at $723,664,000 after buying an additional 696,965 shares during the period. 79.46% of the stock is owned by institutional investors.
Edwards Lifesciences Stock Performance
NYSE EW traded up $0.22 on Wednesday, hitting $72.09. 2,864,353 shares of the company's stock traded hands, compared to its average volume of 4,800,358. The firm's 50-day moving average price is $71.59 and its two-hundred day moving average price is $70.59. The firm has a market capitalization of $42.38 billion, a PE ratio of 10.34, a P/E/G ratio of 4.82 and a beta of 1.15. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $95.25.
Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, analysts expect that Edwards Lifesciences Co. will post 2.45 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of analysts recently weighed in on the stock. Citigroup upped their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a "buy" rating in a research note on Wednesday, December 11th. Piper Sandler boosted their price target on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Barclays increased their price objective on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Canaccord Genuity Group boosted their price objective on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a "hold" rating in a research note on Thursday, February 13th. Finally, Morgan Stanley upped their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and eleven have given a buy rating to the company's stock. According to data from MarketBeat.com, Edwards Lifesciences presently has an average rating of "Hold" and an average target price of $79.95.
Read Our Latest Report on Edwards Lifesciences
Insider Activity at Edwards Lifesciences
In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the company's stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares in the company, valued at approximately $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Bernard J. Zovighian sold 6,164 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the sale, the chief executive officer now owns 59,083 shares in the company, valued at $4,106,859.33. This trade represents a 9.45 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 62,553 shares of company stock worth $4,513,064. 1.29% of the stock is owned by corporate insiders.
Edwards Lifesciences Profile
(
Free Report)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Further Reading
Before you consider Edwards Lifesciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.
While Edwards Lifesciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
